BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 21715564)

  • 1. VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations.
    Rechsteiner MP; von Teichman A; Nowicka A; Sulser T; Schraml P; Moch H
    Cancer Res; 2011 Aug; 71(16):5500-11. PubMed ID: 21715564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
    Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
    Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance.
    Razafinjatovo C; Bihr S; Mischo A; Vogl U; Schmidinger M; Moch H; Schraml P
    BMC Cancer; 2016 Aug; 16():638. PubMed ID: 27530247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
    Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC
    Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
    Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
    Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
    Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
    Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
    Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
    Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
    Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.
    Nyhan MJ; El Mashad SM; O'Donovan TR; Ahmad S; Collins C; Sweeney P; Rogers E; O'Sullivan GC; McKenna SL
    Cell Oncol (Dordr); 2011 Jun; 34(3):225-34. PubMed ID: 21547579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tuberous sclerosis complex protein 1 expression is affected by VHL Gene alterations and HIF-1α production in sporadic clear-cell renal cell carcinoma.
    Damjanovic SS; Ilic BB; Beleslin Cokic BB; Antic JA; Bankovic JZ; Milicevic IT; Rodic GS; Ilic DS; Todorovic VN; Puskas N; Tulic CD
    Exp Mol Pathol; 2016 Dec; 101(3):323-331. PubMed ID: 27845047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity.
    Hansen WJ; Ohh M; Moslehi J; Kondo K; Kaelin WG; Welch WJ
    Mol Cell Biol; 2002 Mar; 22(6):1947-60. PubMed ID: 11865071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
    Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
    Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinoma.
    Gossage L; Pires DE; Olivera-Nappa Á; Asenjo J; Bycroft M; Blundell TL; Eisen T
    Hum Mol Genet; 2014 Nov; 23(22):5976-88. PubMed ID: 24969085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel VHL target genes and relationship to hypoxic response pathways.
    Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
    Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deubiquitylase OTUD6B stabilizes the mutated pVHL and suppresses cell migration in clear cell renal cell carcinoma.
    Guo K; Wei Y; Wang Z; Zhang X; Zhang X; Liu X; Wu W; Wu Z; Zhang L; Cui CP
    Cell Death Dis; 2022 Feb; 13(2):97. PubMed ID: 35110537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma.
    Luu VD; Boysen G; Struckmann K; Casagrande S; von Teichman A; Wild PJ; Sulser T; Schraml P; Moch H
    Clin Cancer Res; 2009 May; 15(10):3297-304. PubMed ID: 19401348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.
    Casagrande S; Ruf M; Rechsteiner M; Morra L; Brun-Schmid S; von Teichman A; Krek W; Schraml P; Moch H
    J Pathol; 2013 Mar; 229(4):525-34. PubMed ID: 23007793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations.
    Li L; Zhang L; Zhang X; Yan Q; Minamishima YA; Olumi AF; Mao M; Bartz S; Kaelin WG
    Mol Cell Biol; 2007 Aug; 27(15):5381-92. PubMed ID: 17526729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma.
    Sorrell AD; Lee S; Stolle C; Ellenhorn J; Grix A; Kaelin WG; Weitzel JN
    Clin Genet; 2011 Jun; 79(6):539-45. PubMed ID: 20560986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.